NDAINJECTIONINJECTABLE
Approved
Jul 1954
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 16h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
SURITAL (thiamylal sodium) is a barbiturate injectable anesthetic approved in 1954 for intravenous administration. It is used for induction and maintenance of general anesthesia in surgical and diagnostic procedures. The drug works by enhancing GABAergic inhibition in the central nervous system, producing rapid onset sedation and anesthesia.
LOE Approaching
This legacy injectable anesthetic faces erosion as modern alternatives dominate the market; commercial teams are likely in maintenance mode with minimal growth investments.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
This product offers limited career momentum; roles are primarily focused on lifecycle management, maintaining existing relationships, and defending market share against modern alternatives. Career growth and learning opportunities are constrained by the product's mature, declining stage and low linked job volume.
Product Manager (Legacy)Field Sales (Specialty Anesthesia)
Worked on SURITAL at Pfizer? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.